Literature DB >> 12044503

Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game.

M Gion1, P Boracchi, R Dittadi, E Biganzoli, L Peloso, R Mione, C Gatti, A Paccagnella, E Marubini.   

Abstract

The aims of the present investigation were to evaluate the association between serum CA15.3 levels and other biological and clinical variables and its prognostic role in patients with node-negative breast cancer. We evaluated 362 patients operated upon primary breast cancer from 1982 to 1992 (median follow-up 69 months). Serum CA15.3 was measured by an immunoradiometric assay. The association between variables was investigated by a Principal Component Analysis (PCA) and the prognostic role of CA15.3 on relapse-free survival (RFS) was investigated by Cox regression models adjusting for age, oestrogen receptor (ER), tumour stage, and ER x age interaction, with both the likelihood ratio test and Harrell's c statistic. The prognostic contribution of CA 15.3 was highly significant. Log relative hazard of relapse was constant until approximately 10 (U/ml) of CA15.3 and increased thereafter with increasing marker levels. CA15.3 showed a significant contribution using as a cut-off point a value of 31 U/ml. However, the contribution to the model of the marker as a continuous variable is much greater. From these findings, we can conclude that: (i) CA15.3 is a prognostic marker in node-negative breast cancer; (ii) its relationship with prognosis is continuous, with the risk of relapse increasing progressively from approximately 10 U/ml.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12044503     DOI: 10.1016/s0959-8049(01)00426-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  13 in total

1.  CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.

Authors:  Brigitte Rack; Julia Jückstock; Elisabeth Trapp; Tobias Weissenbacher; Marianna Alunni-Fabbroni; Amelie Schramm; Peter Widschwendter; Krisztian Lato; Thomas Zwingers; Ralf Lorenz; Hans Tesch; Andreas Schneeweiss; Peter Fasching; Sven Mahner; Matthias W Beckmann; Werner Lichtenegger; Wolfgang Janni
Journal:  Tumour Biol       Date:  2016-08-01

2.  Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value.

Authors:  Rafael Molina; Jose M Augé; Jose M Escudero; Xavier Filella; Gabriel Zanon; Jaume Pahisa; Blanca Farrus; Montserrat Muñoz; Martin Velasco
Journal:  Tumour Biol       Date:  2010-04-02

Review 3.  FDG PET and tumour markers in the diagnosis of recurrent and metastatic breast cancer.

Authors:  Wulf Siggelkow; Werner Rath; Udalrich Buell; Michael Zimny
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-14       Impact factor: 9.236

Review 4.  Breast cancer circulating biomarkers: advantages, drawbacks, and new insights.

Authors:  Andrea Ravelli; James M Reuben; Francesco Lanza; Simone Anfossi; Maria Rosa Cappelletti; Laura Zanotti; Angela Gobbi; Chiara Senti; Paola Brambilla; Manuela Milani; Daniele Spada; Paolo Pedrazzoli; Massimo Martino; Alberto Bottini; Daniele Generali
Journal:  Tumour Biol       Date:  2015-08-26

Review 5.  Circulating tumour markers in breast cancer.

Authors:  Ettore Seregni; Antonio Coli; Nicola Mazzucca
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-04       Impact factor: 9.236

6.  Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer.

Authors:  Mohamed Elfagieh; Fathi Abdalla; Asma Gliwan; Jamela Boder; Wafa Nichols; Abdelbaset Buhmeida
Journal:  Tumour Biol       Date:  2012-09-05

7.  Symptomatic metastasis prediction with serial measurements of CA 15.3 in primary breast cancer patients.

Authors:  Amir Bahrami-Ahmadi; Fariborz Makarian; Mohammad R Mortazavizadeh; Mohammad F Yazdi; Mehdi Chamani
Journal:  J Res Med Sci       Date:  2012-09       Impact factor: 1.852

8.  Protein biomarkers for the early detection of breast cancer.

Authors:  David E Misek; Evelyn H Kim
Journal:  Int J Proteomics       Date:  2011-08-11

Review 9.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

10.  Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples.

Authors:  Anna Kazarian; Oleg Blyuss; Gergana Metodieva; Aleksandra Gentry-Maharaj; Andy Ryan; Elena M Kiseleva; Olga M Prytomanova; Ian J Jacobs; Martin Widschwendter; Usha Menon; John F Timms
Journal:  Br J Cancer       Date:  2017-01-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.